In patients with Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established. We evaluated the prognostic impact of individual ACAs in 152 patients with Ph1 ALL receiving first-line intensive chemotherapy plus either imatinib (n 5 36), dasatinib (n 5 74), or ponatinib (n 5 42). ACAs were identified in 118 patients (78%). Compared to outcomes of patients without ACAs, ACAs were not associated with differences in either relapse-free survival (RFS; P 5 0.42) or overall survival (OS; P 5 0.51).
| M E T H O D S

| Patients
Between June 2001 and January 2016, 182 adults with previously untreated Ph1 ALL received induction with hyperfractionated cyclophosphamide, vincristine (or liposomal vincristine), doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine (i.e. the hyper-CVAD regimen) plus a TKI at our institution. [10] [11] [12] The TKI was continued indefinitely as maintenance therapy. Allogeneic stem cell transplantation (ASCT) was performed at the discretion of the treating physician. Thirty patients positive for BCR-ABL1 by fluorescent in situ hybridization and/or polymerase chain reaction (PCR) but who had diploid cytogenetics or insufficient metaphases were excluded from the analysis. Of the 152 evaluable patients, the TKI received was imatinib in 36 (24%), dasatinib in 74 (49%), and ponatinib in 42 (28%). Median duration of follow-up was 43 months (range, 2-173 months).
| Response definitions
A complete molecular response (CMR) was defined as the absence of a quantifiable BCR-ABL1 transcript by PCR with a sensitivity of 0.01%.
Relapse was defined by recurrence of >5% blasts in a bone marrow aspirate or by the presence of extramedullary disease. RFS was calculated from the time of complete remission until relapse or death. OS was calculated from the time of treatment initiation until death.
| Statistical methods
RFS and OS were calculated using Kaplan-Meier estimates, and survival estimates were compared using the log-rank test. Univariate Cox proportional hazards regression models were used to assess the association between patient characteristics and RFS or OS. Patient characteristics with P < 0.10 in the univariate analyses were included in the multivariate model; backward elimination was used until all predictors had a P < 0.05.
| R E S U L T S
| ACA frequencies
Baseline characteristics are shown in Table 1 . Of the 152 evaluable patients in whom the Ph was detected, 34 (22%) had t(9;22) alone and 118 (78%) also had one or more ACAs. Median age was similar between patients with and without ACAs (55 years and 54 years, respectively, P 5 0.98). Among the 118 patients with ACAs, 25 (17%) were high hyperdiploidy (HeH; defined as 51-65 chromosomes); no patients with low hypodiploidy (defined as 30-39 chromosomes) were identified. Excluding ACAs associated with chromosomal gain in the 25 patients with HeH, the recurrent ACAs identified in 5% of the remaining ACA population (n 5 118) were: 27/7q in 24 (20%), 1der(22)t(9;22) in 15 (16%), 29/9p in 15 (16%), 121 in 8 (7%), 18 in 7 (6%) and translocations of 1q21 in 7 (6%). Among patients with translocations of 1q21, none had identical translocations. 
| Outcomes by individual ACAs
The 5-year RFS and OS rates were similar between the t(9;22) alone and ACA groups (RFS: 59% and 53%, respectively, P 5 0.42; OS: 57% and 56%, respectively, P 5 0.51). When individual ACA groups were compared, distinct prognostic groups were identified (Table 2 ). In the absence of HeH, patients with 1der (22) The median RFS and OS for this poor-risk group were 16 and 22 months, and 5-year RFS and OS rates were 33% and 24%, respectively.
In contrast, patients with ACAs other than 1der (22) rate 33% versus 59%, respectively; P 5 0.01; Figure 1A ) and OS Abbreviations: ACA, additional chromosomal abnormalities; HeH, high hyperdiploidy; OS, overall survival; RFS, relapse-free survival. 
| Univariate and multivariate analysis for RFS and OS
Univariate analysis of variables associated with RFS and OS is shown in 
| DISCUSSION
We have shown that 1der(22)t(9;22) and 29/9p in the absence of HeH constitute a group of poor-risk ACAs that are independently associated with a 2-fold higher risk of relapse or death in patients with Ph1 ALL who are treated with chemotherapy plus a TKI. Notably, the prognostic impact of these poor-risk ACAs did not appear to be mediated by differences in rates of CMR. These findings suggest that the presence of these poor-risk ACAs, which are present in 16% of patients with Ph1 ALL, should be considered when planning postremission therapies.
The presence of 1der(22)t(9;22) has previously been shown to confer an inferior prognosis in patients with chronic myeloid leukemia receiving TKI treatment 13 although its significance in Ph1 ALL in the pre-TKI era has been mixed. 3, 4, 9 Similarly, reports of the clinical significance of abnormalities of chromosome 9 in Ph1 ALL have yielded conflicting results. [2] [3] [4] 6, 9 Many of these studies were performed in the pre-TKI era and were limited by relatively small sample sizes. Our study, which includes a large number of patients, defines of the impact of ACAs in Ph1 ALL in the TKI era and shows that these two ACAs are independently associated with poor outcomes. In our study, the prognostic impact of 1der (22) was restricted to patients without HeH. We found that HeH was associated with favorable outcomes, even when 1der(22)t(9;22) or 29/9p
was also present. HeH has been well-established to be associated with superior survival in adults with ALL, although most studies have primarily evaluated patients with Philadelphia chromosome-negative disease. [14] [15] [16] Our finding that the negative prognostic influence of 1der(22)t(9;22) and 29/9p is restricted to patients without HeH highlights that HeH ALL is a unique clinical entity, including among patients with Ph1 ALL. Furthermore, our exclusion of patients with HeH from analysis of the impact of individual ACAs likely explains the discrepancy between our findings and some previous studies that did not find a negative impact of 1der(22)t(9;22) or 29/9p. For example, one prior study of ACAs in Ph1 ALL suggested that the presence of 1der(22)t (9;22) was associated with a lower risk for relapse. 9 However, there was significant overlap of cases with HeH and 1der(22)t(9;22), which may have confounded the results.
To our knowledge, only one prior report has described the negative prognostic impact of 1der(22)t(9;22) and 29/9p in patients with Ph1 ALL treated with chemotherapy plus a TKI. 7 Our study corroborates these findings using a cohort of patients who received three different TKIs and which had a notably lower rate of ASCT in first remission (75% versus 22%). While we found that poor-risk ACAs were independently prognostic for RFS and OS when baseline characteristics and TKI were considered, the negative outcomes of these poor-risk ACAs were driven primarily by the patients treated with imatinib and dasatinib. Although the number of patients treated with ponatinib was relatively small, it is notable that poor-risk ACAs appeared not to have an adverse prognostic impact in the ponatinib cohort.
These results therefore suggest that ponatinib may be able to negate the unfavorable prognostic influence of these poor-risk ACAs seen when earlier-generation TKIs are used.
Although achievement of CMR at 3 months has been established as a strong prognostic factor for patients with Ph1 ALL, 17 the CMR rates were similar between patients with and without poor-risk ACAs,
suggesting that the differential outcomes of these two groups is not mediated by initial depth of response. This raises the question of whether the higher rates of relapse seen in the poor-risk ACA group may be due in part to an increased likelihood of TKI resistance in patients harboring these poor-risk ACAs. To address this question, future studies should integrate genomic profiling and ABL1 kinase mutation analysis to elucidate the mechanisms by which these poorrisk ACAs lead to inferior outcomes in patients with Ph1 ALL.
In conclusion, in patients with Ph1 ALL receiving chemotherapy plus a TKI, the presence of 1der (22) 
